Biohaven Pharmaceutical Hld

Biohaven Ltd. operates as a biopharmaceutical company that focuses on neurological and neuropsychiatric diseases. Its portfolio includes treatments for medical needs including focal epilepsy, obsessive compulsive disorder, spinocerebellar ataxia and spinal muscular atrophy. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

PALO ALTO, Calif.--( BUSINESS WIRE )--Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief licensing advisor (East) in the New York office.

Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor

Biohaven Ltd. (BHVN) delivered earnings and revenue surprises of 30.83% and 100%, respectively, for the quarter ended September 2022.

Biohaven Ltd. (BHVN) Reports Q3 Loss, Misses Revenue Estimates

Biohaven Ltd. launched post-closing of the Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments

ACM Research

Akouos

Cano Health

FingerMotion

Immunovant Inc

Ngm Biopharmaceuticals Inc

Nutex Health Inc

Tango Therapeutics

TuSimple Holdings

Small-cap stocks can offer big returns in a short period of time, especially when the economy is rebounding from a slowdown.

These Were the Five Best and Worst Performing Small-cap Stocks in October 2022

Biohaven Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy?

Biohaven advances development of its extracellular target degrader platform technology (MoDEs™) for therapies across a variety of diseases including neuroscience, immunology and oncology Through its continued collaboration with Yale University in the laboratory of Professor David Spiegel and Biohaven Labs, Biohaven has made further innovations in this ground-breaking technology with new patent applications covering additional targets and functionality In-licensed from Yale University in 2021, the MoDE platform is based on patent applications filed by Yale in 2018 and 2019 NEW HAVEN, Conn. , Oct. 25, 2022 /PRNewswire/ -- Biohaven Ltd.

Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University

NEW HAVEN, Conn. , Oct. 20, 2022 /PRNewswire/ -- Biohaven Ltd.

Biohaven Announces Pricing of Public Offering of Common Shares

NEW HAVEN, Conn. , Oct. 18, 2022 /PRNewswire/ -- Biohaven Ltd.

Biohaven Announces Launch of Public Offering of Common Shares

Biohaven Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume.

Biohaven Ltd. (BHVN) Surges 7.6%: Is This an Indication of Further Gains?

Biohaven's most valuable migraine-related assets were recently acquired by Pfizer for $11.6 billion. This has left a far smaller stub of cash and other pharmaceutical assets now trading as Biohaven that may be worth around $24/share, well above the current price.

Biohaven Stub May Provide An Interesting Setup For Investors

The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.

Biohaven (BHVN) Stock Up on Spin-Off Transaction Finalization

The "new" Biohaven is enjoying plenty of attention from investors.

Why Biohaven Stock Skyrocketed Again Today

The "old" Biohaven is gone, leaving the "new" Biohaven to rise.

Why Biohaven Stock Is Soaring Today

Broad therapeutic research and development portfolio includes more than 13 clinical and pre-clinical programs with a focus on neuroscience and rare disorders including epilepsy, pain and mood disorders, obsessive compulsive disorder (OCD), spinocerebellar ataxia (SCA) and spinal muscular atrophy (SMA). Excitement mounting for clinical stage neuroscience program in Kv7 Ion Channel Modulation which targets key subunits involved in neuronal signaling and plays a critical role in regulating the hyperexcitable state in epilepsy and potentially other central nervous system (CNS) disorders.

Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients

Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study.

Biohaven Pharma's (BHVN) ALS Study Fail to Meet Both Endpoints

Biohaven Pharmaceutical said Thursday its experimental ALS treatment failed in a midstage study, leading BHVN stock to dip slightly. The post Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test appeared first on Investor's Business Daily.

Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test

NEW HAVEN, Conn. , Sept. 29, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)

NEW HAVEN, Conn. , Sept. 18, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Announces Record Date for Anticipated Spin-Off

Amazon

Salesforce

Dollar General

Alphabet

Healthcare Realty Trust Inc

Eli Lilly

Microsoft

Neurocrine Biosciences

PayPal

Seagen

Snowflake

T-Mobile US

Big investors are famous for breaking rank from the S&P 500 crowd. So when you see a few agreeing on a stock, it's worth paying attention.

15 Stocks Billionaire Investors Agree It's Smart To Buy Now

Results from this study demonstrate a robust and clinically meaningful reduction in barbiturate use after the initiation of Nurtec ODT, providing an alternative migraine therapy for those who may be reliant on butalbital or desire an alternative therapy that is not associated with addiction potential. Despite being associated with addiction potential, medication overuse (rebound) headaches and central nervous system side effects, barbiturates are prescribed as first-line migraine treatments.

Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT

SAN FRANCISCO--(BUSINESS WIRE)--Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing. MBX Capital led the round and was joined by PsyMed Ventures, Village Global and The Yale Startup, among others. The new financing will help the company advance its current lead ketamine program as well as further multiple additional exploratory program

Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments

CareMax

Hanger Inc

Meridian Bioscience

NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) 's  sale to Pfizer Inc. for $148.50 per share in cash.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, VIVO, HNGR, CMAX

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. BHVN also reports a wider-than-expected Q2 loss.

Biohaven Pharmaceutical (BHVN) Q2 Earnings Lag, Sales Beat

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -122.58% and 2.75%, respectively, for the quarter ended June 2022.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates

Antitrust approvals have been granted by the relevant governing authorities, including the Federal Trade Commission ("FTC"), with respect to the previously announced Pfizer Inc. acquisition of Biohaven Pharmaceutical Holding Company Ltd.; preliminary proxy statement has been filed with the SEC NURTEC® ODT (rimegepant) TRx volumes grew 11% and net product revenue was $194 million, up sequentially 57% Anticipated closing of the merger agreement necessitates accounting of derivative losses in the amount of $1.57 per share resulting in a total second quarter reported net loss of $6.21 per share; non-GAAP adjusted net loss1 for the second quarter was $3.82 per share Featured 31 new and encore presentations, including three late-breakers and three oral presentations, spotlighting robust Nurtec ODT and zavegepant migraine data at the 64th annual scientific meeting of the American Headache Society; oral presentations included first of its kind study in migraine reporting on the safety and benefits of Nurtec ODT when used as preventive treatment and as-needed for acute treatment of migraine Zavegepant nasal spray New Drug Application ("NDA") filing accepted by the U.S. Food and Drug Administration ("FDA"), with a Prescription Drug User Fee Act goal date set for first quarter of 2023 Commenced enrollment in Phase 3 clinical trial assessing efficacy and safety of taldefgrobep alfa in patients with Spinal Muscular Atrophy NEW HAVEN, Conn.

Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments

News for Biohaven Pharmaceutical Hld Stock (BHVN)